Global Fund C19RM update

Awards

20 September 2021
Global Fund C19RM update

Peter Sands
Global Fund C19RM update

FUNDING REQUESTS AND AWARDS OVERVIEW

C19RM Status of Awards Submissions and Pipeline

82% or US$2,685 million of C19RM 2021 funding is awarded or recommended for Board Approval to 105 applicants (either Fast-Track or Full Review) for a portfolio average of 21.9% of HTM allocation.

Full Funding requests: US$2,093 million was awarded or recommended for Board approval to 99 applicants.

Fast-track Funding Requests: US$591 million was awarded to 36 applicants.

Including Unfunded Demand of US$1,002 million for 65 applicants, the total of IC Decisions is up to US$4,123 million. This includes US$436 million of activities not approved.

Demand pipeline: 18% or US$601 million has been submitted or under review for potential C19RM 2021 funding. US$164 million is projected for submission or resubmission.

C19RM Awarded & Requested amounts

- Total requested amount: US$4,887 million
- IC Decisions: US$2,685 million
- Pipeline*: US$601 million
- Available Funds**: US$3,315 million
- Demand in excess of available funds: US$1,137 million

*Pipeline includes: submissions under review, in screening and projected submissions/resubmissions.

**Additional contribution from CH and NL subject to AFC approval.

All values are in US$ million and rounded.

For values in screening and under review even incomplete submissions are reported.

(as of Sept 17)
86% of $2,685 million of C19RM investments are directed towards ACT-A Gap Filling Activities given most awards to date are via Fast-Track and Full Funding Request prioritize reinforcing the COVID-19 response. These investments are split across the Diagnostics Pillar ($723 million or 27%), the Therapeutics Pillar ($689 million or 26%), and Health Systems Connector ($894 million or 33%).

As more Full Funding Requests are reviewed and awards made, we expect that the share of complementary activities will increase.
Global Fund C19RM update

C19RM Award by Health Products

Health product investments are more balanced across key Health Products. Approximately 65% of awards to date are expected to use wambo as the procurement channel.

FUNDING REQUESTS AND AWARDS OVERVIEW

C19RM Awards by type

- Total awards (HP and non-HP): $2,685
- DX RDT: $257
- DX PCR: $376
- PPE: $469
- O2: $467
- TX other: $155
- Other non-HP awards: $961

Values above include Fast track awards, Full funding requests awarded and/or recommended for board approval. Differences in values between Global Fund defined health products are accounted for by a more limited set of products that are included under these categories.

All values in the charts are in USD million and rounded. Recent awards values may be adjusted slightly once HPMTs are finalized.

(as of Sept 17)